DDX11抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P08470(DDX11 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08470(DDX11 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The DDX11 antibody is a key reagent for studying the function of DDX11 (DEAD-box helicase 11), a member of the DEAD-box protein family involved in DNA replication, repair, and sister chromatid cohesion. DDX11. also known as ChlR1. exhibits ATP-dependent RNA/DNA helicase activity critical for resolving G-quadruplex structures and maintaining genomic stability during cell division. Antibodies targeting DDX11 enable researchers to investigate its expression, localization, and interactions in cellular processes like mitotic progression and DNA damage response.

These antibodies are widely used in techniques such as Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to study DDX11's role in diseases linked to chromosomal instability. For instance, DDX11 mutations are associated with Warsaw breakage syndrome, a rare disorder characterized by microcephaly and growth defects, while its overexpression has been observed in certain cancers. Validated DDX11 antibodies are essential for distinguishing between wild-type and dysfunctional variants, as well as exploring its potential as a therapeutic target.

Most commercial DDX11 antibodies are raised against specific epitopes (e.g., N-terminal or helicase domains) in hosts like rabbits or mice. Rigorous validation, including siRNA knockdown or knockout controls, ensures specificity. Their applications span basic research on genome maintenance to clinical studies on cancer progression, underscoring DDX11's significance in cellular homeostasis and disease pathology.

(Word count: 245)